Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors

The primary objective of the study is to evaluate the efficacy of radiofrequency treatment of grade 1 NF-PNETS with a size less than or equal to 2cm.

Patients meeting the selection criteria will be included in the study after signing the consent. They will benefit from a RFA treatment consisting of 1 to 3 sessions depending on their response to the treatment. Patients will then be followed for 5 years in order to evaluate their response to treatment, their clinical evolution, their quality of life and any complications.

Inclusion criteria

• Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;
• Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67<3%,
• Non-secretory lesion.
• Homogeneous HEE contrast taking;
• No positron emission tomography (PET) FDG binding to the pancreatic mass;
• Lesion <20mm on conventional imaging at 6 months monitoring;
• Age 18 to 80 years inclusive;
• Patient in good general condition, World Health Organization [0-1];
• Signed consent to participate;
• Affiliation to healthcare insurance system or beneficiary of this regimen.

Exclusion criteria

• Pregnant or likely to become pregnant (without effective contraception) or breastfeeding ;
• A person in an emergency situation or deprived of liberty or placed under the authority of a tutor.
• Life expectancy < 1 year;
• Severe hemostasis disorders;
• Pancreatic and/or biliary ductal dilation;
• Lesion considered to be adjacent to the pancreatic duct and/or bile duct;
• Node extension and/or metastatic disease;
• Patient being managed for another malignant lesion which is progressive or under treatment.